Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

EU: AG advises ECJ to rule that patented DNA can only be protected as chemical substance where it performs function for which it is patented: Monsanto v Cefetra (Managing Intellectual Property) (IPKat) (EPLAW)

Mexico: Supreme Court decides on broad interpretation of linkage regulations (Patent Docs)

Global Fund reports on progress toward UN health goals (IP Watch)

Patent World article ‘Attacks on Supplementary Protection Certifications’ (The SPC Blog)

Africa: Uganda, Tanzania, Rwanda, Burundi and Sudan refuse to endorse a proposal by the East African Community (EAC) to introduce an anti-counterfeit products law (Afro-IP)

Canada: I’m still your baby: Canada’s continuing support of US linkage regulations for pharmaceuticals (IP Osgoode)

EU: Swiss type claims are no longer acceptable at the EPO: In re Abbott Respiratory (Patent Docs) (IP Osgoode)

EU: AG advises ECJ to rule that patented DNA can only be protected as chemical substance where it performs function for which it is patented: Monsanto v Cefetra (Managing Intellectual Property) (IPKat) (EPLAW)

Mexico: Supreme Court decides on broad interpretation of linkage regulations (Patent Docs)

UK: Medicines fees change from 1 April – reference to paediatric extensions and SPCs (The SPC Blog)

US: Genetic Technologies files suit in W D Wisconsin against nine life science companies alleging infringement of patented ‘junk DNA’ technology (IP Whiteboard)

US: Financial implications of recent US decision on patent term adjustments involving Wyeth (IP finance)

US: ‘Complaint for false patent marking’ – have you received one? If not, you might soon! (FDA Law Blog)

US: Review and correction of patent term adjustment calculation made by the USPTO: Boehringer Ingelheim Pharma GmbH & Co. KG et al. v. Kappos (Patent Docs)

US: New York Times provides soapbox for data exclusivity critics (Patent Docs)

US: Massachusetts Institute of Technology dismissed as party in RNAi dispute: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e V et al v Whitehead Institute for Biomedical Research et al (Patent Docs)

US: Cordis awarded fees and costs in surgical device suit: Marctec v Johnson & Johnson and Cordis Corporation (Patent Docs)

US: Review and correction of patent term adjustment calculation made by the USPTO: Boehringer Ingelheim Pharma GmbH & Co. KG et al. v. Kappos (Patent Docs)

US: False marking complaint filed in E D Pennsylvania concerning Risperdone [sic], Nizoral, Terconazole, Ofloxacin products: Hollander v. Ortho-McNeil-Janssen Pharmaceuticals, Inc. (Patent Docs)

US: CAFC affirms ITC’s final determination of invalidity of two patents for violating best mode requirement and unenforceability of one patent due to inequitable conduct: Ajinomoto Co., Inc v ITC (ITC 337 Law Blog)

Aldara (Imiquimod) – FDA rules against forfeiture for generic Aldara cream (FDA Law Blog)

Flomax (Tamsulosin) – US: Has Ranbaxy intentionally forfeited 180-day exclusivity for monetary benefit? (Patentcircle) (GenericsWeb)

Glazide (Gliclazidium) – Poland: Supreme Administrative Court: Glazide is distinctive (Class 46)

Januvia (Sitagliptin) – EU: Partial translation of German Sitagliptin referral to the ECJ (The SPC Blog)

Nexium IV (Esomeprazole) – US: Infringement of patent following a Paragraph IV certification: AstraZeneca AB et al. v. Sun Pharma Global FZE et al. (Patent Docs) (GenericsWeb)

Protonix (Pantoprazole) – US: District Court dismisses Wyeth Lanham Act case concerning generic Protonix, but leaves the door open for further litigation (FDA Law Blog)

ReFacto (Moroctocog alfa)– US: Novartis prevails over Pfizer in ReFacto suit (Patent Docs)

Vytorin (Ezetimibe, Simvastatin) – US: Infringement of patent following a Paragraph IV certification: Schering Corp. et al. v. Teva Pharmaceuticals USA, Inc. et al (Patent Docs)